Skip to main content
Windlas Biotech Limited logo

Windlas Biotech Limited — Investor Relations & Filings

Ticker · WINDLAS ISIN · INE0H5O01029 LEI · 3358008HGGLMCSC4GP83 BSE.NS Manufacturing
Open in API
Filings indexed 433 across all filing types
Latest filing 2025-11-07 Regulatory Filings
Country IN India
Listing BSE.NS WINDLAS

About Windlas Biotech Limited

https://www.windlasbiotech.com

Windlas Biotech Limited is a Contract Development and Manufacturing Organization (CDMO) providing integrated services from formulation development to commercial-scale production. The company specializes in manufacturing solid and liquid oral dosage forms, including tablets, capsules, sachets, and liquid orals. Its operations encompass three primary business verticals: CDMO services for domestic and multinational firms, trade generics, and over-the-counter (OTC) brands. Windlas maintains advanced research and development facilities focused on process optimization and complex generic formulations. The product portfolio covers diverse therapeutic areas such as gastrointestinal, cardiovascular, anti-diabetic, and respiratory health. The company emphasizes scalable manufacturing solutions and adherence to global quality standards to support the product lifecycles of its pharmaceutical partners.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter from Windlas Biotech Limited addressed to stock exchanges, informing them about the recording of a conference call related to the unaudited financial results for the quarter and half year ended September 30, 2025. It mentions that the audio recording has been uploaded and that the transcript will be shared later. The document is short (1759 characters) and serves as an intimation or announcement rather than containing the actual transcript or financial data. Therefore, it is not the full Call Transcript (CT) but an announcement about it. According to the rules, such announcements about report availability or recordings are classified as Regulatory Filings (RNS).
2025-11-07 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a detailed financial results presentation for the quarter and half year ended September 30, 2025 (Q2 and H1 FY26). It includes comprehensive financial data such as revenue, EBITDA, PAT, EPS, segment performance, management commentary, and outlook. The document is addressed to stock exchanges under SEBI (LODR) Regulations, 2015, and is titled as a "Results Presentation." It is not merely an announcement of results but contains substantive financial data and analysis for the interim period. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length (9675 characters) supports it being a full report rather than a brief announcement or press release. Hence, the appropriate classification is IR with high confidence.
2025-11-06 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled 'Windlas Biotech Limited Investor Presentation – Q2 & H1FY26' and is addressed to stock exchanges under Regulation 30(6) of SEBI (LODR) Regulations, 2015, indicating a regulatory disclosure. It contains detailed financial performance data for the quarter and half year ended September 30, 2025 (Q2 & H1 FY26), including revenue, EBITDA, PAT, segment-wise performance, management commentary, and business highlights. The document is about 15,000 characters long, which is substantial and contains detailed financial and operational information. The presence of slides, tables, and management commentary aligns with the characteristics of an investor presentation. It is not a full annual or interim report, nor is it a brief earnings release or a regulatory filing. Therefore, the document fits best into the 'Investor Presentation' category.
2025-11-06 English
Outcome of Board Meeting
Regulatory Filings
2025-11-06 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter from Windlas Biotech Limited addressed to stock exchanges, informing about the schedule of a conference call to discuss the financial performance for the quarter and half year ended September 30, 2025. It references a conference call invite and provides dial-in details for the call. There is no actual financial data or detailed report content included, only an announcement of the upcoming earnings call. According to the classification rules, such a document is best classified as a Call Transcript (CT) if it contained the full transcript, but since this is only a schedule and invitation for the call, it is an announcement related to the earnings call. The closest fitting category is Earnings Release (ER) if it contained key financial highlights, but this document does not contain financial results, only the schedule. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about the conference call schedule without substantive financial data or transcript content.
2025-10-29 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-10-29 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.